| Mr Will E Coltharp Jr, MSN, APN | |
|
2067 Upland Dr, Franklin, TN 37067-4090 | |
| (615) 794-1814 | |
| (615) 794-1840 |
| Full Name | Mr Will E Coltharp Jr |
|---|---|
| Gender | Male |
| Speciality | Certified Clinical Nurse Specialist (cns) |
| Experience | 30 Years |
| Location | 2067 Upland Dr, Franklin, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558592519 | NPI | - | NPPES |
| 3341920 | Medicaid | TN |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Psych Services Llc | 4587551163 | 3 |
News Archive
In the neurological train wreck that is stroke, researchers have traced the major cause of the death of brain cells due to artery blockage or bleeding in the brain.
Stroke is the third leading cause of death and a major source of disability in the United States. Every year about 700,000 people in the United States suffer a stroke, resulting in nearly 158,000 deaths.
Tibotec Pharmaceuticals today announced its submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TMC278 (rilpivirine, as hydrochloride), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV. The proposed indication would make TMC278 available for once-daily use with other antiretroviral agents in treatment-naive HIV-1-infected adults.
A preliminary study suggests that kidney paired donation transplantation, in which incompatible donor/recipient pairs exchange kidneys so that each recipient receives a compatible kidney, had graft survival rates equivalent to compatible live donor transplants, according to a study in the October 5 issue of JAMA: The Journal of the American Medical Association.
› Verified 6 days ago
| Entity Name | Psych Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689640468 PECOS PAC ID: 4587551163 Enrollment ID: O20040228000356 |
News Archive
In the neurological train wreck that is stroke, researchers have traced the major cause of the death of brain cells due to artery blockage or bleeding in the brain.
Stroke is the third leading cause of death and a major source of disability in the United States. Every year about 700,000 people in the United States suffer a stroke, resulting in nearly 158,000 deaths.
Tibotec Pharmaceuticals today announced its submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TMC278 (rilpivirine, as hydrochloride), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV. The proposed indication would make TMC278 available for once-daily use with other antiretroviral agents in treatment-naive HIV-1-infected adults.
A preliminary study suggests that kidney paired donation transplantation, in which incompatible donor/recipient pairs exchange kidneys so that each recipient receives a compatible kidney, had graft survival rates equivalent to compatible live donor transplants, according to a study in the October 5 issue of JAMA: The Journal of the American Medical Association.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Will E Coltharp Jr, MSN, APN 2067 Upland Dr, Franklin, TN 37067-4090 Ph: (615) 794-1814 | Mr Will E Coltharp Jr, MSN, APN 2067 Upland Dr, Franklin, TN 37067-4090 Ph: (615) 794-1814 |
News Archive
In the neurological train wreck that is stroke, researchers have traced the major cause of the death of brain cells due to artery blockage or bleeding in the brain.
Stroke is the third leading cause of death and a major source of disability in the United States. Every year about 700,000 people in the United States suffer a stroke, resulting in nearly 158,000 deaths.
Tibotec Pharmaceuticals today announced its submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TMC278 (rilpivirine, as hydrochloride), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV. The proposed indication would make TMC278 available for once-daily use with other antiretroviral agents in treatment-naive HIV-1-infected adults.
A preliminary study suggests that kidney paired donation transplantation, in which incompatible donor/recipient pairs exchange kidneys so that each recipient receives a compatible kidney, had graft survival rates equivalent to compatible live donor transplants, according to a study in the October 5 issue of JAMA: The Journal of the American Medical Association.
› Verified 6 days ago
Caroline Post Cone, MSN, PMHCNS, BC Clinical Nurse Specialist Medicare: Not Enrolled in Medicare Practice Location: 301 Mallory Station Rd Ste 110, Franklin, TN 37067 Phone: 615-481-9933 |